326 related articles for article (PubMed ID: 23585477)
1. MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
Schlegel J; Sambade MJ; Sather S; Moschos SJ; Tan AC; Winges A; DeRyckere D; Carson CC; Trembath DG; Tentler JJ; Eckhardt SG; Kuan PF; Hamilton RL; Duncan LM; Miller CR; Nikolaishvili-Feinberg N; Midkiff BR; Liu J; Zhang W; Yang C; Wang X; Frye SV; Earp HS; Shields JM; Graham DK
J Clin Invest; 2013 May; 123(5):2257-67. PubMed ID: 23585477
[TBL] [Abstract][Full Text] [Related]
2. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.
Tworkoski KA; Platt JT; Bacchiocchi A; Bosenberg M; Boggon TJ; Stern DF
Pigment Cell Melanoma Res; 2013 Jul; 26(4):527-41. PubMed ID: 23617806
[TBL] [Abstract][Full Text] [Related]
3. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV; Earp HS; Keating AK; Graham DK
PLoS One; 2016; 11(10):e0165107. PubMed ID: 27783662
[TBL] [Abstract][Full Text] [Related]
4. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
Branchford BR; Stalker TJ; Law L; Acevedo G; Sather S; Brzezinski C; Wilson KM; Minson K; Lee-Sherick AB; Davizon-Castillo P; Ng C; Zhang W; Neeves KB; Lentz SR; Wang X; Frye SV; Shelton Earp H; DeRyckere D; Brass LF; Graham DK; Di Paola JA
J Thromb Haemost; 2018 Feb; 16(2):352-363. PubMed ID: 29045015
[TBL] [Abstract][Full Text] [Related]
5. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Sinik L; Minson KA; Tentler JJ; Carrico J; Bagby SM; Robinson WA; Kami R; Burstyn-Cohen T; Eckhardt SG; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Mol Cancer Ther; 2019 Feb; 18(2):278-288. PubMed ID: 30482852
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: MERTK signaling in cancer.
Cummings CT; Deryckere D; Earp HS; Graham DK
Clin Cancer Res; 2013 Oct; 19(19):5275-80. PubMed ID: 23833304
[TBL] [Abstract][Full Text] [Related]
8. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.
Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK
Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326
[TBL] [Abstract][Full Text] [Related]
9. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells.
Png KJ; Halberg N; Yoshida M; Tavazoie SF
Nature; 2011 Dec; 481(7380):190-4. PubMed ID: 22170610
[TBL] [Abstract][Full Text] [Related]
10. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
[TBL] [Abstract][Full Text] [Related]
11. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.
Nguyen KQ; Tsou WI; Calarese DA; Kimani SG; Singh S; Hsieh S; Liu Y; Lu B; Wu Y; Garforth SJ; Almo SC; Kotenko SV; Birge RB
J Biol Chem; 2014 Sep; 289(37):25737-49. PubMed ID: 25074939
[TBL] [Abstract][Full Text] [Related]
13. Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-kappaB transcriptional activation.
Tibrewal N; Wu Y; D'mello V; Akakura R; George TC; Varnum B; Birge RB
J Biol Chem; 2008 Feb; 283(6):3618-3627. PubMed ID: 18039660
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
[TBL] [Abstract][Full Text] [Related]
15. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.
Sensi M; Catani M; Castellano G; Nicolini G; Alciato F; Tragni G; De Santis G; Bersani I; Avanzi G; Tomassetti A; Canevari S; Anichini A
J Invest Dermatol; 2011 Dec; 131(12):2448-57. PubMed ID: 21796150
[TBL] [Abstract][Full Text] [Related]
16. Mer receptor tyrosine kinase negatively regulates lipoteichoic acid-induced inflammatory response via PI3K/Akt and SOCS3.
Zhang B; Fang L; Wu HM; Ding PS; Xu K; Liu RY
Mol Immunol; 2016 Aug; 76():98-107. PubMed ID: 27419619
[TBL] [Abstract][Full Text] [Related]
17. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.
Cackowski FC; Eber MR; Rhee J; Decker AM; Yumoto K; Berry JE; Lee E; Shiozawa Y; Jung Y; Aguirre-Ghiso JA; Taichman RS
J Cell Biochem; 2017 Apr; 118(4):891-902. PubMed ID: 27753136
[TBL] [Abstract][Full Text] [Related]
18. The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma.
Shi C; Li X; Wang X; Ding N; Ping L; Shi Y; Mi L; Lai Y; Song Y; Zhu J
J Hematol Oncol; 2018 Mar; 11(1):43. PubMed ID: 29554921
[TBL] [Abstract][Full Text] [Related]
19. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
20. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cδ, and p38 mitogen-activated protein kinase (MAPK).
Thorp E; Vaisar T; Subramanian M; Mautner L; Blobel C; Tabas I
J Biol Chem; 2011 Sep; 286(38):33335-44. PubMed ID: 21828049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
